August 2026 · 6 min read
Standard human AB serum comes from healthy, screened-negative donors. For many research and diagnostic applications, that is exactly what you need. But for IVD assay development, biomarker validation, and cross-reactivity testing, you need serum that contains the actual analyte or pathological condition you are measuring — disease state serum.
What is disease state serum?
Disease state serum is human serum collected from donors with a defined, confirmed medical condition. Unlike standard serum — which is screened to exclude infectious agents and pathological markers — disease state serum is specifically collected from donors who test positive for a target analyte or carry a defined condition. It is the positive control material and challenge matrix for assay development.
Disease state serum is not a research tool for studying the disease itself — it is a quality control and assay validation reagent for diagnostic test developers, immunoassay manufacturers, and biomarker researchers who need real-world positive samples.
Key disease state serum categories
Infectious disease markers — for IVD assay development
| Condition | Application | Key notes |
|---|---|---|
| HIV-1/2 positive | Anti-HIV antibody assay development, NAT validation | Ab-positive; RNA-positive (viremic) available separately |
| HBsAg positive (HBV) | HBsAg immunoassay development, surface antigen quantification | Various genotypes available; HBeAg status specified |
| Anti-HCV positive | HCV antibody assay development, confirmatory testing | Seroconversion panels available for window period testing |
| HCV RNA positive | NAT assay development, viral load quantification | Genotype-specific panels available |
| Syphilis (T. pallidum) positive | Treponemal antibody assay development | RPR/VDRL titres specified |
| HTLV-I/II positive | Blood bank screening assay development | Rare — request availability |
Autoimmune and inflammatory conditions
| Condition | Application |
|---|---|
| Rheumatoid factor (RF) positive | Interference testing in immunoassays — RF is a major interferent in many sandwich ELISAs |
| ANA positive (various patterns) | Anti-nuclear antibody assay development, autoimmune panel validation |
| Anti-dsDNA positive | SLE biomarker assay development |
| Anti-CCP positive | Rheumatoid arthritis assay development |
| High-sensitivity CRP elevated | hsCRP assay calibration and linearity verification |
Metabolic and hormonal conditions
| Condition / Marker | Application |
|---|---|
| 25-OH Vitamin D deficient (<10 ng/mL) | Vitamin D immunoassay calibration — low-end linearity |
| 25-OH Vitamin D replete (>30 ng/mL) | Normal range calibrator base matrix |
| Hyperlipidemic (elevated triglycerides) | Lipemia interference testing (CLSI EP7) |
| Icteric (elevated bilirubin) | Icterus interference testing |
| Haemolytic (elevated free haemoglobin) | Haemolysis interference testing |
| Thyroid disorders (hypo/hyperthyroid) | TSH, T3, T4 assay development |
How disease state serum is used in IVD development
1. Cross-reactivity testing
Regulatory submissions for IVD devices (EU IVDR 2017/746, FDA 510(k)) require demonstration that the assay does not cross-react with potentially interfering conditions. For an HIV antibody test, you must demonstrate no false positives in serum from donors with rheumatoid factor, ANA, HBV, HCV, malaria, and other conditions likely to be present in the tested population. Disease state serum panels provide the challenge samples for this validation.
2. Assay sensitivity at the clinical decision limit
The clinical sensitivity of a diagnostic assay is measured by its ability to detect the analyte at or near the clinical decision threshold — the concentration above which a patient tests positive. Disease state serum with confirmed low-positive analyte concentrations (near the cutoff) tests the assay’s lower limit of detection under real-world matrix conditions.
3. Interference testing (CLSI EP7)
Lipemic, icteric, and haemolytic serum samples are standard challenge materials for the CLSI EP7 interference protocol — required for most IVD submissions. SeamlessBio supplies pooled lipemic (triglycerides >1,000 mg/dL), icteric (bilirubin >20 mg/dL), and haemolytic (haemoglobin >500 mg/dL) human serum for this application.
4. Seroconversion panels for window period characterisation
HIV and HCV seroconversion panels — sequential samples from donors collected before, during, and after seroconversion — allow characterisation of how early an assay can detect infection. These are among the most valuable and difficult-to-source materials in IVD development.
Regulatory and ethical considerations
Disease state serum is collected under informed consent from donors who are aware of their diagnosis and agree to use of their samples for research and diagnostic development. All SeamlessBio disease state serum is supplied with:
- Donor informed consent documentation (framework certificate)
- Confirmed diagnostic test results for the defined condition
- Standard infectious disease screening panel (HIV, HBV, HCV, syphilis NAT)
- CoA with protein and albumin content
- Lot-specific availability — quantities are limited by donor pool size
Available from SeamlessBio
SeamlessBio supplies disease state human serum for EU and UK customers — infectious disease markers, autoimmune conditions, metabolic disorders, and interference testing panels. Availability is lot-specific. Contact us with your required analyte, titre range, and volume for a quote within 48 hours.
→ Request disease state serum availability | → Human Serum Portfolio
Further reading:
info@seamlessbio.de | +49 851 37932226
English 
Deutsch